Affiliate disclosure: Care Path Compare may receive compensation if you use certain provider links and make a qualifying purchase, at no extra cost to you. Compensation does not determine inclusion, price order, or editorial conclusions.

Semaglutide vs. tirzepatide: Key comparison matrix

The table below summarizes the core pharmacological, clinical, and commercial differences between semaglutide and tirzepatide.

Comparison Parameter Semaglutide (Wegovy / Ozempic) Tirzepatide (Zepbound / Mounjaro)
Drug Class & Mechanism Selective GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist
Manufacturer Novo Nordisk Eli Lilly and Company
Pivotal Weight Loss Brands Wegovy (weight loss), Ozempic (diabetes) Zepbound (weight loss), Mounjaro (diabetes)
Average Weight Loss (Trials) 14.9% of body weight (STEP-1, 68 weeks) 20.9% of body weight (SURMOUNT-1, 72 weeks)
Patients Losing ≥ 20% Weight ~31% of clinical trial participants ~57% of clinical trial participants
Maximum Approved Dose 2.4 mg subcutaneously once weekly 15.0 mg subcutaneously once weekly
Dosing Escalation Steps 5 monthly increments (0.25 to 2.4 mg) 6 monthly increments (2.5 to 15.0 mg)
Cardiovascular Risk Indication FDA-approved to reduce CV death & stroke Under active clinical investigation (SURPASS-CVOT)
Kidney Disease Protection FDA-approved for CKD risk reduction in T2D Under evaluation in ongoing clinical trials
Manufacturer List Price ~$969 (Ozempic) to ~$1,349 (Wegovy) / month ~$1,059 (Zepbound) to ~$1,069 (Mounjaro) / month
LillyDirect Cash Vials Not available (autoinjector pens only) $399 (2.5 mg) to $549 (5.0 mg) / month
Vetted 503A Compounded Option Wellmedr ($49/mo) / Collective ($59/mo) Wellmedr ($89/mo) / Collective ($69/mo)

Mechanism of action: Single vs. dual incretin receptor stimulation

The central clinical distinction between semaglutide and tirzepatide lies in their receptor pharmacology. Both drugs utilize native gut hormones (incretins) that regulate insulin, satiety, and digestive speed, but tirzepatide adds an entirely separate hormonal pathway.

INCRETIN RECEPTOR MECHANISM COMPARISON:

SEMAGLUTIDE (Single Incretin Agonist):
[GLP-1 Receptor Agonist] ──► Delays Gastric Emptying ──► Enhances Satiety
                          ──► Stimulates Beta-Cell Insulin
                          ──► Suppresses Glucagon Release

TIRZEPATIDE (Dual Incretin Agonist / "Twincretin"):
[GLP-1 Receptor Agonist] ──► Satiety Signaling & Glycemic Control
          +
[GIP Receptor Agonist]   ──► Improves Adipose Tissue Insulin Sensitivity
                          ──► Buffers Postprandial Free Fatty Acids
                          ──► Synergistic Central Appetite Regulation

1. How Semaglutide Works (Pure GLP-1 Agonist)

Semaglutide is a modified 31-amino-acid peptide that selectively binds to human glucagon-like peptide-1 (GLP-1) receptors. In the pancreas, it stimulates insulin secretion from beta cells in a glucose-dependent manner while simultaneously suppressing inappropriate glucagon secretion from alpha cells.

In the gastrointestinal tract and brain, semaglutide slows down gastric motility (delaying stomach emptying) and activates appetite-regulating centers in the hypothalamus. This prolonged fullness significantly reduces caloric intake.

2. How Tirzepatide Works (Dual GIP + GLP-1 Agonist)

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP is naturally secreted in response to dietary fat and carbohydrates and accounts for approximately two-thirds of the normal incretin effect.

By stimulating GIP receptors in combination with GLP-1 receptors:

  • Insulin Sensitivity: GIP enhances insulin sensitivity in peripheral tissues and modulates adipose tissue lipid metabolism, promoting healthier fat storage and buffering circulating free fatty acids.
  • Central Synergy: Dual receptor stimulation in brain satiety circuits produces a more potent appetite-suppressing effect than stimulating the GLP-1 receptor alone.
  • Tolerability Balancing: Clinical evidence suggests that GIP activity may partially buffer against some of the gastrointestinal adverse effects caused by high-intensity GLP-1 receptor stimulation.

Clinical trial results: Which drug causes more weight loss?

When evaluating weight-loss efficacy, researchers have compared semaglutide and tirzepatide through both direct head-to-head clinical trials and large pivotal obesity studies.

The NEJM SURPASS-2 Head-to-Head Trial

The most authoritative head-to-head data comes from the SURPASS-2 trial, published in The New England Journal of Medicine, which directly compared three doses of tirzepatide (5 mg, 10 mg, and 15 mg) against the standard 1.0 mg maintenance dose of semaglutide in 1,879 patients with type 2 diabetes over 40 weeks:

  • HbA1c Reduction: Tirzepatide reduced HbA1c by 2.01% to 2.30%, compared to 1.86% with semaglutide.
  • Body Weight Loss: Patients on tirzepatide 15 mg lost an average of 11.2 kg (24.7 lbs), compared to 5.7 kg (12.6 lbs) on semaglutide 1.0 mg—demonstrating nearly double the weight reduction.
  • Statistical Significance: Tirzepatide met all primary and key secondary endpoints for both non-inferiority and superiority over semaglutide.

Obesity Trials: STEP-1 (Wegovy) vs. SURMOUNT-1 (Zepbound)

In patients treated specifically for chronic weight management without type 2 diabetes, the differences in weight-loss magnitude remain pronounced:

WEIGHT LOSS PERCENTAGE COMPARISON:

Wegovy 2.4 mg (STEP-1, 68 Weeks):
Average Loss: [███████████████] 14.9% of body weight (~34 lbs)
Lost ≥ 15%:   [████████████] 50.5% of patients
Lost ≥ 20%:   [███████] 31.1% of patients

Zepbound 15.0 mg (SURMOUNT-1, 72 Weeks):
Average Loss: [█████████████████████] 20.9% of body weight (~52 lbs)
Lost ≥ 15%:   [████████████████] 62.9% of patients
Lost ≥ 20%:   [██████████████] 56.7% of patients
Lost ≥ 25%:   [█████████] 36.2% of patients
  • Wegovy 2.4 mg (STEP-1): Average weight reduction of 14.9% at 68 weeks. Approximately one-third (31.1%) of patients achieved 20% or greater weight loss.
  • Zepbound 15.0 mg (SURMOUNT-1): Average weight reduction of 20.9% at 72 weeks. More than half (56.7%) of patients achieved 20% or greater weight loss, and over one-third (36.2%) lost 25% or more of their baseline weight.
  • The SURMOUNT-5 Trial: Eli Lilly has completed enrollment for the open-label SURMOUNT-5 trial, which directly pits maximum-dose Wegovy (2.4 mg) against maximum-dose Zepbound (15 mg) head-to-head in non-diabetic adults with obesity.

Side effects and tolerability: How do they compare?

Both semaglutide and tirzepatide share a similar safety profile, dominated by mild-to-moderate gastrointestinal adverse events that occur predominantly during initial dose escalation:

Common Gastrointestinal Symptoms

Reported Adverse Event Semaglutide (Wegovy 2.4 mg) Tirzepatide (Zepbound 15.0 mg)
Nausea ~44% ~28%–31%
Diarrhea ~30% ~23%
Vomiting ~24% ~12%–18%
Constipation ~24% ~17%
Dyspepsia / Acid Reflux ~9% ~10%
Abdominal Pain ~20% ~10%
Treatment Discontinuation 7.0% due to adverse events 4.3%–7.1% due to adverse events

While individual patient experiences vary widely, clinical data indicates that tirzepatide is associated with slightly lower rates of nausea and vomiting relative to its weight-loss potency. Clinicians attribute this to GIP receptor activity, which appears to moderate the nausea signals induced by intense GLP-1 receptor agonism.

Shared Boxed Warning & Serious Precautions

Both medications carry identical FDA Boxed Warnings regarding thyroid C-cell tumors:

  • In rodent carcinogenicity studies, both semaglutide and tirzepatide caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).
  • Absolute Contraindication: Both drugs are contraindicated in patients with a personal or family history of MTC, or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Pancreatitis & Gallbladder Disease: Both medications require immediate discontinuation if acute pancreatitis is suspected. Rapid weight reduction on either drug increases the incidence of gallstones (cholelithiasis) and gallbladder inflammation.

Costs, insurance coverage, and telehealth alternatives

The choice between semaglutide and tirzepatide frequently hinges on financial access, employer coverage rules, and out-of-pocket costs.

1. Brand Name Retail Prices and Insurance Realities

  • Brand Semaglutide (Wegovy): List price is ~$1,349 per 28-day supply. While covered by some commercial employer health plans, many employers exclude anti-obesity medications (AOMs) entirely to contain drug spending.
  • Brand Tirzepatide (Zepbound): List price is ~$1,059 per 28-day supply. Eli Lilly offers LillyDirect single-dose self-pay vials ($399/month for 2.5 mg and $549/month for 5.0 mg), but higher maintenance doses (7.5 mg to 15 mg) must be purchased in autoinjector pens ($1,059/month or $650 with manufacturer savings card).
  • Medicare Part D Exclusions: Under the Medicare Modernization Act of 2003 (MMA), Medicare Part D is legally barred from covering weight-loss medications. While Wegovy has limited coverage for cardiovascular risk reduction in patients with established heart disease, standard weight-loss prescribing remains excluded.

2. State-Licensed 503A Compounded Telehealth Options

Because brand-name list prices exceed $1,000 per month without insurance, millions of American consumers utilize clinician-supervised compounded telehealth programs:

  • Compounded Semaglutide: Telehealth platforms like Wellmedr offer compounded semaglutide starting at $49 for the initial month, while Collective provides flat-rate pricing starting at $59 per month, including medical consultations, provider messaging, and home delivery from licensed 503A compounding pharmacies.
  • Compounded Tirzepatide: Because tirzepatide is a more complex dual-peptide molecule, compounding costs are slightly higher. Wellmedr provides compounded tirzepatide starting at $89 for the initial month, and Collective offers flat-rate plans from $69 per month.

Decision framework: Which medication should you choose?

When deciding between semaglutide and tirzepatide, consider the following clinical and practical factors in consultation with your healthcare provider:

When Tirzepatide May Be the Superior Option

  1. You Have a High Weight-Loss Goal (≥ 20%): If you need to lose more than 40–50 pounds, tirzepatide’s 20.9% average trial weight loss provides a significantly greater probability of reaching substantial metabolic targets.
  2. You Plateaued on Semaglutide: Patients who reached maximum semaglutide dosing (2.4 mg) and experienced a weight-loss plateau frequently resume active weight reduction after switching to tirzepatide’s dual-incretin mechanism.
  3. Severe Metabolic Syndrome or Insulin Resistance: Tirzepatide’s GIP receptor agonism provides enhanced insulin-sensitizing effects in peripheral tissues.

When Semaglutide May Be the Superior Option

  1. You Need the Most Affordable Entry Price: Compounded semaglutide telehealth programs start as low as $49–$59 per month, making it significantly more accessible for cash-paying patients on a strict budget.
  2. Established Cardiovascular Disease (Without Diabetes): Wegovy carries a formal FDA-approved label indication for reducing major adverse cardiovascular events (heart attack, stroke, CV death) based on the 17,604-patient SELECT trial.
  3. Moderate Weight-Loss Goal (10%–15%): For patients seeking to lose 20–30 pounds to resolve borderline hypertension or joint discomfort, semaglutide’s 14.9% average reduction is fully sufficient.

Affiliate disclosure: Care Path Compare may receive compensation if you use a provider link and make a qualifying purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.